Skip to main content

ARCH Venture Management, LLC

13F filer · CIK 0001274403
Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$1.1BU.S. long equity reported on 13F
Positions123 new · 1 closed
Net flow last quarter+$313MBuys minus sells
Top 10 positions weight99.3%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202612 positions
PBLSParabilis Medicines, Inc.$176M15.95%5.26%NewQ2 2026
BEAMBeam Therapeutics Inc.$156M14.16%4.40%Not reportedQ2 2024
RAPPRapport Therapeutics, Inc.$155M14.12%7.78%Not reportedQ2 2024
SPTXSeaport Therapeutics, Inc.$137M12.42%11.76%NewQ2 2026
ERASErasca, Inc.$130M11.81%2.27%Not reportedQ4 2021
VIRVir Biotechnology, Inc.$129M11.76%7.50%-1.7%Q2 2025
MAZEMaze Therapeutics, Inc.$123M11.18%7.42%Not reportedQ1 2025
LYELLyell Immunopharma, Inc.$45.5M4.14%13.88%Not reportedQ2 2025
GENBGenerate Biomedicines, Inc.$32.8M2.98%1.52%Not reportedQ1 2026
TXG10x Genomics, Inc.$8.35M0.76%0.17%Not reportedQ4 2025
BOLDBoundless Bio, Inc.$6.74M0.61%11.99%NewQ2 2026
GOSSGossamer Bio, Inc.$1.33M0.12%1.65%Not reportedQ3 2023
Q1 2026Reported May 15, 202610 positions
MAZEMaze Therapeutics, Inc.$123M18.16%8.28%Not reportedQ1 2025
RAPPRapport Therapeutics, Inc.$117M17.23%7.80%Not reportedQ2 2024
VIRVir Biotechnology, Inc.$116M17.09%8.01%Not reportedQ2 2025
ERASErasca, Inc.$115M16.95%2.28%-35.9%Q4 2021
BEAMBeam Therapeutics Inc.$108M15.98%4.42%Not reportedQ2 2024
LYELLyell Immunopharma, Inc.$65.1M9.62%13.92%+17.7%Q2 2025
GENBGenerate Biomedicines, Inc.$24.3M3.59%1.52%NewQ1 2026
TXG10x Genomics, Inc.$4.62M0.68%0.17%-70.5%Q4 2025
GOSSGossamer Bio, Inc.$2.65M0.39%3.43%Not reportedQ3 2023
QTTBQ32 Bio Inc.$2.06M0.30%2.19%Not reportedQ1 2024
Q4 2025Reported Feb 17, 20269 positions
MAZEMaze Therapeutics, Inc.$171M26.19%8.35%Not reportedQ1 2025
BEAMBeam Therapeutics Inc.$126M19.31%4.46%Not reportedQ2 2024
RAPPRapport Therapeutics, Inc.$113M17.36%7.81%Not reportedQ2 2024
LYELLyell Immunopharma, Inc.$84.9M13.03%12.98%Not reportedQ2 2025
VIRVir Biotechnology, Inc.$77.9M11.95%9.26%Not reportedQ2 2025
ERASErasca, Inc.$41.1M6.31%3.89%Not reportedQ4 2021
GOSSGossamer Bio, Inc.$25M3.83%3.45%Not reportedQ3 2023
TXG10x Genomics, Inc.$12M1.85%0.58%NewQ4 2025
QTTBQ32 Bio Inc.$1.06M0.16%2.49%Not reportedQ1 2024
Q3 2025Reported Nov 14, 20259 positions
RAPPRapport Therapeutics, Inc.$111M22.49%7.83%Not reportedQ2 2024
BEAMBeam Therapeutics Inc.$110M22.38%4.48%Not reportedQ2 2024
MAZEMaze Therapeutics, Inc.$107M21.70%8.57%Not reportedQ1 2025
VIRVir Biotechnology, Inc.$73.8M14.98%9.29%Not reportedQ2 2025
LYELLyell Immunopharma, Inc.$44.8M9.10%14.30%+51.5%Q2 2025
ERASErasca, Inc.$24.1M4.89%3.90%Not reportedQ4 2021
GOSSGossamer Bio, Inc.$21.2M4.30%3.48%Not reportedQ3 2023
QTTBQ32 Bio Inc.$635K0.13%2.60%Not reportedQ1 2024
CEROCero Therapeutics Holdings, Inc.$114K0.02%1.86%Not reportedQ1 2024
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.